Eli Lilly has shown patients maintained most of their weight loss after switching from injectable GLP-1s to its oral drug ...

Early Thursday, Takeda revealed top-line data for two pivotal phase 3 trials of its next-gen, highly selective oral tyrosine ...

The biotech is advancing its new lead candidate, CMP-002, while working with BioMarin on assets that engage regRNA sequences ...

Neurology biotech Voyager Therapeutics has laid off 30 employees, a spokesperson for the Massachusetts-based company ...

With a late-stage miss reported for its prospective social anxiety disorder (SAD) treatment fasedienol, Vistagen’s chances at ...

Clinical development accelerator Quotient Sciences and CRO Lindus Health are joining forces to create a streamlined process for clients to advance from first-in-human (FIH) up to pivotal trials.

The former director of the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID ...

Vir Biotechnology is handing off certain commercial rights for its hepatitis D program to European specialty pharma Norgine ...

“Built on years of global clinical use data, Versius Plus delivers the flexibility and intelligence today’s healthcare ...

After layoffs this fall, Mythic Therapeutics is winding down, putting all its assets up for sale and terminating its only ...

Medline—the mammoth medical device distributor that has largely worked behind the scenes and out of the headlines to stock ...

Medtronic reported that its new thrombectomy system, aimed at removing blood clots from the arms and legs, has begun its ...